Avanir Pharmaceuticals (Nasdaq: AVNR) is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. Avanir’s products and product candidates address therapeutic markets that include central nervous system disorders, inflammation and infectious disease.

Zenvia™, Avanir's lead product candidate for the treatment of pseudobulbar affect (PBA), also known as involuntary emotional expression disorder (IEED), is the subject of an approvable letter from the FDA and future development plans for this product candidate are under consideration.  The Company does not know at this time what impact, if any, the ongoing discussions with the FDA for PBA may have on the development of Zenvia for other indications. 

Avanir has licensed certain compounds to Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease.

The Company's first commercialized product, abreva^®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores.

Avanir Pharmaceuticals' corporate office is located at 101 Enterprise, Suite 300, Aliso Viejo, CA 92656.